Sheldon Koenig
Chief Executive Officer chez ESPERION THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Postes actifs de Sheldon Koenig
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ESPERION THERAPEUTICS, INC. | Director/Board Member | 18/05/2021 | - |
| Chief Executive Officer | 18/05/2021 | - | |
| President | 18/05/2021 | - | |
| Chief Operating Officer | 15/12/2020 | 18/05/2021 | |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Director/Board Member | - | - |
| Founder | - | - |
Historique de carrière de Sheldon Koenig
Anciens postes connus de Sheldon Koenig
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 28/01/2019 | 01/08/2020 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2009 | 01/01/2015 |
| Sanofi Corp. | Corporate Officer/Principal | 01/01/2015 | - |
Formation de Sheldon Koenig
| Drexel University | Undergraduate Degree |
| Monmouth University | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 8 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ESPERION THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
| Sanofi Corp. | |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Health Technology |
- Bourse
- Insiders
- Sheldon Koenig
- Expérience
